Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate

Samantha L. Sampson, Keith G. Mansfield, Angela Carville, Dewey Magee, Teresa Quitugua, Elizabeth W. Howerth, Barry R. Bloom, Mary K. Hondalus

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We have previously described the development of a live, fully attenuated Mycobacterium tuberculosis (Mtb) vaccine candidate strain with two independent attenuating auxotrophic mutations in leucine and pantothenate biosynthesis. In the present work, those studies have been extended to include testing for protective efficacy in a long-term guinea pig survival model and safety testing in the highly tuberculosis susceptible Rhesus macaque. To model the safety of the ΔleuD ΔpanCD strain in HIVinfected human populations, a Simian immunodeficiency virus (SIV)-infected Rhesus macaque group was included. Immunization with the non-replicating ΔleuD ΔpanCD conferred long-term protection against challenge with virulent M. tuberculosis equivalent to that afforded by BCG as measured by guinea pig survival. In safety studies, clinical, hematological and bacteriological monitoring of both SIV-positive and SIV-negative Rhesus macaques immunized with ΔleuD ΔpanCD, revealed no vaccine-associated adverse effects. The results support the further development of the ΔleuD ΔpanCD strain as a viable tuberculosis (TB) vaccine candidate.

Original languageEnglish (US)
Pages (from-to)4839-4847
Number of pages9
JournalVaccine
Volume29
Issue number29-30
DOIs
StatePublished - Jun 24 2011

Fingerprint

Simian immunodeficiency virus
auxotrophs
Simian Immunodeficiency Virus
Mycobacterium tuberculosis
Macaca mulatta
Tuberculosis Vaccines
Leucine
leucine
Vaccines
vaccines
Safety
tuberculosis
guinea pigs
Guinea Pigs
safety testing
Mycobacterium bovis
human population
clinical trials
Immunization
immunization

Keywords

  • Auxotroph
  • Guinea pig
  • Rhesus macaque
  • SIV
  • Tuberculosis
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. / Sampson, Samantha L.; Mansfield, Keith G.; Carville, Angela; Magee, Dewey; Quitugua, Teresa; Howerth, Elizabeth W.; Bloom, Barry R.; Hondalus, Mary K.

In: Vaccine, Vol. 29, No. 29-30, 24.06.2011, p. 4839-4847.

Research output: Contribution to journalArticle

Sampson, Samantha L. ; Mansfield, Keith G. ; Carville, Angela ; Magee, Dewey ; Quitugua, Teresa ; Howerth, Elizabeth W. ; Bloom, Barry R. ; Hondalus, Mary K. / Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. In: Vaccine. 2011 ; Vol. 29, No. 29-30. pp. 4839-4847.
@article{003e27b3ff8e44b5b1d011061afce732,
title = "Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate",
abstract = "We have previously described the development of a live, fully attenuated Mycobacterium tuberculosis (Mtb) vaccine candidate strain with two independent attenuating auxotrophic mutations in leucine and pantothenate biosynthesis. In the present work, those studies have been extended to include testing for protective efficacy in a long-term guinea pig survival model and safety testing in the highly tuberculosis susceptible Rhesus macaque. To model the safety of the ΔleuD ΔpanCD strain in HIVinfected human populations, a Simian immunodeficiency virus (SIV)-infected Rhesus macaque group was included. Immunization with the non-replicating ΔleuD ΔpanCD conferred long-term protection against challenge with virulent M. tuberculosis equivalent to that afforded by BCG as measured by guinea pig survival. In safety studies, clinical, hematological and bacteriological monitoring of both SIV-positive and SIV-negative Rhesus macaques immunized with ΔleuD ΔpanCD, revealed no vaccine-associated adverse effects. The results support the further development of the ΔleuD ΔpanCD strain as a viable tuberculosis (TB) vaccine candidate.",
keywords = "Auxotroph, Guinea pig, Rhesus macaque, SIV, Tuberculosis, Vaccine",
author = "Sampson, {Samantha L.} and Mansfield, {Keith G.} and Angela Carville and Dewey Magee and Teresa Quitugua and Howerth, {Elizabeth W.} and Bloom, {Barry R.} and Hondalus, {Mary K.}",
year = "2011",
month = "6",
day = "24",
doi = "10.1016/j.vaccine.2011.04.066",
language = "English (US)",
volume = "29",
pages = "4839--4847",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "29-30",

}

TY - JOUR

T1 - Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate

AU - Sampson, Samantha L.

AU - Mansfield, Keith G.

AU - Carville, Angela

AU - Magee, Dewey

AU - Quitugua, Teresa

AU - Howerth, Elizabeth W.

AU - Bloom, Barry R.

AU - Hondalus, Mary K.

PY - 2011/6/24

Y1 - 2011/6/24

N2 - We have previously described the development of a live, fully attenuated Mycobacterium tuberculosis (Mtb) vaccine candidate strain with two independent attenuating auxotrophic mutations in leucine and pantothenate biosynthesis. In the present work, those studies have been extended to include testing for protective efficacy in a long-term guinea pig survival model and safety testing in the highly tuberculosis susceptible Rhesus macaque. To model the safety of the ΔleuD ΔpanCD strain in HIVinfected human populations, a Simian immunodeficiency virus (SIV)-infected Rhesus macaque group was included. Immunization with the non-replicating ΔleuD ΔpanCD conferred long-term protection against challenge with virulent M. tuberculosis equivalent to that afforded by BCG as measured by guinea pig survival. In safety studies, clinical, hematological and bacteriological monitoring of both SIV-positive and SIV-negative Rhesus macaques immunized with ΔleuD ΔpanCD, revealed no vaccine-associated adverse effects. The results support the further development of the ΔleuD ΔpanCD strain as a viable tuberculosis (TB) vaccine candidate.

AB - We have previously described the development of a live, fully attenuated Mycobacterium tuberculosis (Mtb) vaccine candidate strain with two independent attenuating auxotrophic mutations in leucine and pantothenate biosynthesis. In the present work, those studies have been extended to include testing for protective efficacy in a long-term guinea pig survival model and safety testing in the highly tuberculosis susceptible Rhesus macaque. To model the safety of the ΔleuD ΔpanCD strain in HIVinfected human populations, a Simian immunodeficiency virus (SIV)-infected Rhesus macaque group was included. Immunization with the non-replicating ΔleuD ΔpanCD conferred long-term protection against challenge with virulent M. tuberculosis equivalent to that afforded by BCG as measured by guinea pig survival. In safety studies, clinical, hematological and bacteriological monitoring of both SIV-positive and SIV-negative Rhesus macaques immunized with ΔleuD ΔpanCD, revealed no vaccine-associated adverse effects. The results support the further development of the ΔleuD ΔpanCD strain as a viable tuberculosis (TB) vaccine candidate.

KW - Auxotroph

KW - Guinea pig

KW - Rhesus macaque

KW - SIV

KW - Tuberculosis

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=79960649514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960649514&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.04.066

DO - 10.1016/j.vaccine.2011.04.066

M3 - Article

VL - 29

SP - 4839

EP - 4847

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 29-30

ER -